Lutetium-177 DOTATATE

• Class: Peptide receptor radionuclide therapy (PRRT).
• Type: Radiolabeled somatostatin analog.

Mechanism of Action (MOA)

• DOTATATE is a somatostatin analog that binds somatostatin receptor subtype 2 (SSTR2), overexpressed on neuroendocrine tumor (NET) cells.
• Conjugated to Lutetium-177, a beta-emitting radionuclide.
• Delivers targeted radiation → DNA damage and tumor cell death (“cross-fire” effect kills nearby cells).

Clinical Uses

• Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs):
  • Advanced, unresectable, or metastatic tumors.
  • Typically after progression on somatostatin analog therapy (octreotide or lanreotide).

Dosing (Adults)

• 7.4 GBq (200 mCi) IV infusion every 8 weeks, for 4 cycles.
• Infuse over ~30–40 minutes.
• Co-administer amino acid solution (lysine/arginine) to protect kidneys from radiation nephrotoxicity.

Toxicities

• Hematologic: anemia, thrombocytopenia, neutropenia – usually transient.
• Renal toxicity – mitigated by amino acid infusion.
• Nausea/vomiting – often due to amino acid infusion.
• Fatigue.
• Rare: hepatotoxicity, secondary myelodysplastic syndrome (MDS) or leukemia.
• Hypersensitivity reactions – uncommon.

Monitoring

• CBC prior to each cycle.
• Renal function (creatinine, GFR) before and during therapy.
• Liver function tests.
• Monitor for nausea during amino acid infusion.
• Follow radiation safety protocols for handling patient excreta.

Summary

Lutetium-177 DOTATATE (Lutathera®) is a PRRT agent for somatostatin receptor-positive GEP-NETs. Key concerns are hematologic toxicity, renal protection, nausea management, and radiation safety, requiring amino acid co-infusion and careful monitoring of blood counts and renal function.